UroGen Pharma Ltd. specializes in creating non-surgical therapies for specialty cancers and urologic conditions. The company's core technology is RTGel, a sustained-release, hydrogel-based platform that allows for prolonged exposure of urinary tract tissue to medications. Its commercial portfolio features JELMYTO, a treatment for low-grade upper tract urothelial cancer, and ZUSDURI, an intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products utilize the chemotherapy agent mitomycin formulated with RTGel to ablate tumors locally. By focusing on targeted drug delivery within the urinary system, UroGen provides alternatives to invasive surgical procedures.
